Wuxi Pharmatech Enters Into Definitive Merger Agreement

Go back to Wuxi Pharmatech Enters Into Definitive Merger Agreement

William Blair Downgrades WuXi PharmaTech (WX) to Market Perform

August 17, 2015 7:36 AM EDT

William Blair downgraded WuXi PharmaTech (NYSE: WX) from Outperform to Market Perform.

For an analyst ratings summary and ratings history on WuXi PharmaTech click here. For more ratings news on WuXi PharmaTech click here.

Shares of WuXi PharmaTech closed at $43.86 yesterday.

... More

WuXi PharmaTech (WX) Enters $46/ADS Merger Agreement

August 14, 2015 6:36 AM EDT

WuXi PharmaTech (NYSE: WX) announced that it has entered into a definitive Agreement and Plan of Merger (the "Merger Agreement") with New WuXi Life Science Limited ("Parent") and WuXi Merger Limited ("Merger Sub"), a wholly owned subsidiary of Parent.

Pursuant to the Merger Agreement, Parent will acquire the Company for cash consideration equal to US$5.75 per ordinary share of the Company (each, a "Share") and US$46 per American Depositary Share of the Company, each representing eight Shares (each, an "ADS"), or approximately US$3.3 billion in aggregate cash consideration. This represents a 16.5%... More